123 related articles for article (PubMed ID: 38320051)
1. Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment.
Donovan JL; Hamdy FC; Lane JA; Young GJ; Metcalfe C; Walsh EI; Davis M; Steuart-Feilding T; Blazeby JM; Avery KNL; Martin RM; Bollina P; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Rosario DJ; Rowe E; Mason M; Catto JWF; Peters TJ; Wade J; Turner EL; Williams NJ; Oxley J; Staffurth J; Bryant RJ; Neal DE
NEJM Evid; 2023 Apr; 2(4):EVIDoa2300018. PubMed ID: 38320051
[TBL] [Abstract][Full Text] [Related]
2. Functional Outcomes After Localized Prostate Cancer Treatment.
Al Hussein Al Awamlh B; Wallis CJD; Penson DF; Huang LC; Zhao Z; Conwill R; Talwar R; Morgans AK; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; O'Neil BB; Koyama T; Hoffman KE; Barocas DA
JAMA; 2024 Jan; 331(4):302-317. PubMed ID: 38261043
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
Lane A; Metcalfe C; Young GJ; Peters TJ; Blazeby J; Avery KN; Dedman D; Down L; Mason MD; Neal DE; Hamdy FC; Donovan JL;
BJU Int; 2016 Dec; 118(6):869-879. PubMed ID: 27415448
[TBL] [Abstract][Full Text] [Related]
4. Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).
Lane JA; Donovan JL; Young GJ; Davis M; Walsh EI; Avery KNL; Blazeby JM; Mason MD; Martin RM; Peters TJ; Turner EL; Wade J; Bollina P; Catto JWF; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Oxley J; Paul A; Paez E; Rosario DJ; Rowe E; Staffurth J; Neal DE; Hamdy FC; Metcalfe C;
BJU Int; 2022 Sep; 130(3):370-380. PubMed ID: 35373443
[TBL] [Abstract][Full Text] [Related]
5. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
Donovan JL; Hamdy FC; Lane JA; Mason M; Metcalfe C; Walsh E; Blazeby JM; Peters TJ; Holding P; Bonnington S; Lennon T; Bradshaw L; Cooper D; Herbert P; Howson J; Jones A; Lyons N; Salter E; Thompson P; Tidball S; Blaikie J; Gray C; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Paul A; Powell P; Prescott S; Rosario DJ; Rowe E; Davis M; Turner EL; Martin RM; Neal DE;
N Engl J Med; 2016 Oct; 375(15):1425-1437. PubMed ID: 27626365
[TBL] [Abstract][Full Text] [Related]
6. Patient-Reported Outcomes From a Phase 3 Randomized Controlled Trial Exploring Optimal Sequencing of Short-Term Androgen Deprivation Therapy With Prostate Radiation Therapy in Localized Prostate Cancer.
Roy S; Grimes S; Morgan SC; Eapen L; Malone J; Craig J; Spratt DE; Malone S
Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1101-1113. PubMed ID: 33524545
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer.
Moon DH; Basak RS; Usinger DS; Dickerson GA; Morris DE; Perman M; Lim M; Wibbelsman T; Chang J; Crawford Z; Broughman JR; Godley PA; Chen RC
Eur Urol; 2019 Sep; 76(3):391-397. PubMed ID: 30857758
[TBL] [Abstract][Full Text] [Related]
8. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
[TBL] [Abstract][Full Text] [Related]
9. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry.
Punnen S; Cowan JE; Chan JM; Carroll PR; Cooperberg MR
Eur Urol; 2015 Oct; 68(4):600-8. PubMed ID: 25242555
[TBL] [Abstract][Full Text] [Related]
10. Population-based study of long-term functional outcomes after prostate cancer treatment.
Carlsson S; Drevin L; Loeb S; Widmark A; Lissbrant IF; Robinson D; Johansson E; Stattin P; Fransson P
BJU Int; 2016 Jun; 117(6B):E36-45. PubMed ID: 25959859
[TBL] [Abstract][Full Text] [Related]
11. Impact of age on quality-of-life outcomes after treatment for localized prostate cancer.
Hampson LA; Cowan JE; Zhao S; Carroll PR; Cooperberg MR
Eur Urol; 2015 Sep; 68(3):480-6. PubMed ID: 25656807
[TBL] [Abstract][Full Text] [Related]
12. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL
Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677
[TBL] [Abstract][Full Text] [Related]
13. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.
Potosky AL; Legler J; Albertsen PC; Stanford JL; Gilliland FD; Hamilton AS; Eley JW; Stephenson RA; Harlan LC
J Natl Cancer Inst; 2000 Oct; 92(19):1582-92. PubMed ID: 11018094
[TBL] [Abstract][Full Text] [Related]
14. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
[TBL] [Abstract][Full Text] [Related]
15. Magnetic Resonance-guided Stereotactic Radiotherapy for Localized Prostate Cancer: Final Results on Patient-reported Outcomes of a Prospective Phase 2 Study.
Tetar SU; Bruynzeel AME; Oei SS; Senan S; Fraikin T; Slotman BJ; Moorselaar RJAV; Lagerwaard FJ
Eur Urol Oncol; 2021 Aug; 4(4):628-634. PubMed ID: 32536573
[TBL] [Abstract][Full Text] [Related]
16. Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study.
Mazariego CG; Egger S; King MT; Juraskova I; Woo H; Berry M; Armstrong BK; Smith DP
BMJ; 2020 Oct; 371():m3503. PubMed ID: 33028540
[TBL] [Abstract][Full Text] [Related]
17. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
18. Long-term quality of life outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with androgen deprivation.
Luo HC; Cheng LP; Cheng HH; Fu ZC; Liao SG; Li DS; Zheng WF; Lin GS; Zhu JF; Xu JF; Yin Q; Yu QY
Med Oncol; 2014 Jun; 31(6):991. PubMed ID: 24848281
[TBL] [Abstract][Full Text] [Related]
19. Association of Short-Term Patient-Reported Outcomes With Long-Term Oncologic Outcomes in Localized Prostate Cancer Patients Treated With Radiation Therapy and Androgen Deprivation Therapy in a Randomized Controlled Trial.
Roy S; Spratt DE; Morgan SC; Zhou M; D'Souza LA; Drogos F; Malone J; Grimes S; Gualano C; MacRae R; Mukherjee D; Malone S
Int J Radiat Oncol Biol Phys; 2022 Mar; 112(4):880-889. PubMed ID: 34788698
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial.
Boevé L; Hulshof MCCM; Verhagen PCMS; Twisk JWR; Witjes WPJ; de Vries P; van Moorselaar RJA; van Andel G; Vis AN
Eur Urol; 2021 Feb; 79(2):188-197. PubMed ID: 32978014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
